ENDECE’s lead clinical development candidate, NDC-1308 (MC1) could prove to be an important therapeutic option in minimizing respiratory failure in COVID-19 patients caused by the SARS-CoV-2 virus health emergency and global pandemic.
ENDECE’s Research Effort to Treat COVID-19 Patients
ENDECE is developing a new drug that addresses the deterioration in pulmonary function caused by chronic inflammation in lung tissue and the subsequent risk of acute respiratory failure. Chronic inflammation, a pathology commonly found in many disease states including COVID-19, can lead to respiratory failure and death. This condition is part of Acute Respiratory Distress Syndrome (ARDS).
Pre-clinical research shows that NDC-1308 (MC1), works by directly up-regulating the Lipoprotein Lipase (LPL) gene and functional protein expression, polarizing macrophages to the pro-repair, anti-inflammatory M2-like state. This specific part of the overall mechanism of action of NDC-1308 (MC1) reduces inflammation. ENDECE predicts that NDC-1308 (MC1) could be safely administered via inhalation therapy and could become an important therapeutic approach to minimizing the acute, severe inflammatory response within lung tissue. ENDECE’s approach could significantly reduce the incidence of, or even prevent, acute respiratory failure associated with ARDS and result in a reduction in the number of COVID-19 patients on ventilators and / or reduce “on-ventilator time” in the ICU setting.
A manufacturing process for NDC-1308 (MC1), a small molecule, is scalable and ready to produce quantities required to begin expedited clinical studies in patients suffering from COVID-19. ENDECE is actively pursuing government funding and equity investment to expedite clinical development during this ongoing pandemic.
About ENDECE
ENDECE is a biopharmaceutical company focused on the discovery and development of new therapeutics that stop disease progression, restore function, and improve the lives of people suffering from neurodegenerative and inflammatory diseases. ENDECE is fully committed to creating a healthier future and is proud to serve our community, country and the world.